Submission systemSubmit
Advanced Search
Volume 1 Issue 2
Dec.  2021
Turn off MathJax
Article Contents
Article Navigation >  Frigid Zone Medicine  > 2021  >  1(2): 111-118
Xinyi Liu, Yonghui Pan, Jingjing Wang, Lei Zhang, Junli Zhang. Changes of calcitonin gene-related peptide and other serological indicators in vestibular migraine patients[J]. Frigid Zone Medicine, 2021, 1(2): 111-118. doi: 10.2478/fzm-2021-0014
Citation: Xinyi Liu, Yonghui Pan, Jingjing Wang, Lei Zhang, Junli Zhang. Changes of calcitonin gene-related peptide and other serological indicators in vestibular migraine patients[J]. Frigid Zone Medicine, 2021, 1(2): 111-118. doi: 10.2478/fzm-2021-0014
shu

Changes of calcitonin gene-related peptide and other serological indicators in vestibular migraine patients

doi: 10.2478/fzm-2021-0014
  • 1.

    The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

  • 2.

    The First People's Hospital of Shangqiu, Shangqiu 476005, China

More Information
  • Corresponding author: Yonghui Pan, E-mail: aigui1993@126.com
  • Received Date: 2021-05-17
  • Accepted Date: 2021-06-30
    • Available Online: 2021-12-01
    Abstract
  •   Objective  It aims to evaluate the diagnostic ability of CGRP and other blood indicators in vestibular migraine (VM) patients, and to explain the potential pathological effects of these biomarkers. The hypothesis of VM being a variant of migraine was examined.  Methods   A total of 32 VM patients, 35 migraine patients, and 30 healthy control subjects (HC) were selected for this cross-sectional study. Detailed statistics on demographic data, clinical manifestations, calcitonin gene-related peptide (CGRP) and common clinical laboratory indicators were measured within 24 hours from the onset of the conditions. Receptor operating characteristic (ROC) curve and area under the curve (AUC) were analyzed for biomarkers. The risk factors of VM and migraine were determined through univariate and multivariate analyses.  Results   Compared with HC, serum CGRP levels (p(VM) = 0.012, p(Migraine) = 0.028) increased and Mg2+ levels (p(VM) < 0.001, p (Migraine) < 0.001) deceased in VM patients and migraine patients. In multiple logistic regression, VM was correlated with CGRP [odds ratio (OR) = 1.07; 95% confidence interval (CI), 1.02-1.12; P = 0.01] and Mg2+ [odds ratio (OR) = 0.03; 95% CI, 0.07-0.15; P < 0.001)]. Migraine was correlated with CGRP [odds ratio (OR) = 1.07; 95% CI, 1.02-1.12; P = 0.01] and Mg2+ [odd ratio (OR = 0.01; 95% CI, 0-0.02; P < 0.001)]. Mg2+ discriminated good differentiation between VM and migraine groups, with AUC of 0.649 (95% CI, 0.518 to 0.780). The optimal threshold for Mg2+ to diagnose VM was 0.805.  Conclusions   This study demonstrated that CGRP and Mg2+ may be promising laboratory indicators to discriminate HC from VM/migraine, while Mg2+ may be uded as a discriminator between VM and migraine.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    Li V, McArdle H, Trip S A. Vestibular migraine. BMJ, 2019; 366: l4213.
    [2]
    Xia J, Kong W J, Zhu Y, et al. Intrinsic membrane properties of rat medial vestibular nucleus neurons and their responses to simulated vestibular input signals. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2008; 43(10): 767-772. http://www.ncbi.nlm.nih.gov/pubmed/19119674
    [3]
    Neuhauser H K, Radtke A, Von Brevern M, et al. Migrainous vertigo: prevalence and impact on quality of life. Neurology, 2006; 67(6): 1028-1033. doi: 10.1212/01.wnl.0000237539.09942.06
    [4]
    Fernandez M, Birdi J S, Irving G J, et al. Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev, 2015; 6: CD010600.
    [5]
    Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic criteria. J Vestib Res, 2012; 22(4): 167-172. doi: 10.3233/VES-2012-0453
    [6]
    Alghadir A H, Anwer S. Effects of vestibular rehabilitation in the management of a vestibular migraine: a review. Front Neurol, 2018; 9: 440. doi: 10.3389/fneur.2018.00440
    [7]
    Zhou C, Zhang L, Jiang X, et al. A novel diagnostic prediction model for vestibular migraine. Neuropsychiatr Dis Treat, 2020; 16: 1845-1852. doi: 10.2147/NDT.S255717
    [8]
    Cuccurazzu B, Halberstadt A L. Projections from the vestibular nuclei and nucleus prepositus hypoglossi to dorsal raphe nucleus in rats. Neurosci Lett, 2008; 439(1): 70-74. doi: 10.1016/j.neulet.2008.04.094
    [9]
    Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia, 2019; 39(3): 342-353. doi: 10.1177/0333102417728873
    [10]
    Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia, 2001; 21(2): 96-101. doi: 10.1046/j.1468-2982.2001.00140.x
    [11]
    Tiller-Borcich J K, Capili H, Gordan G S. Human brain calcitonin gene-related peptide (CGRP) is concentrated in the locus caeruleus. Neuropeptides, 1988; 11(2): 55-61. doi: 10.1016/0143-4179(88)90010-8
    [12]
    Emeson R B, Hedjran F, Yeakley J M, et al. Alternative production of calcitonin and CGRP mRNA is regulated at the calcitonin-specific splice acceptor. Nature, 1989; 341(6237): 76-80. doi: 10.1038/341076a0
    [13]
    Tanaka M, Takeda N, Senba E, et al. Localization and origins of calcitonin gene-related peptide containing fibres in the vestibular end-organs of the rat. Acta Otolaryngol Suppl, 1989; 468: 31-34. doi: 10.3109/00016488909139017
    [14]
    Van Rossum D, Hanisch U K, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev, 1997; 21(5): 649-678. doi: 10.1016/S0149-7634(96)00023-1
    [15]
    Xanthos D N, Sandkuhler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci, 2014; 15(1): 43-53. doi: 10.1038/nrn3617
    [16]
    De Hoon J N, Pickkers P, Smits P, et al., Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther, 2003; 73(4): 312-321. doi: 10.1016/S0009-9236(03)00007-9
    [17]
    Sarchielli P, Pini L A, Zanchin G, et al., Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia, 2006; 26(3): 257-265. doi: 10.1111/j.1468-2982.2005.01016.x
    [18]
    Hsu L C, Wang S J, Fuh J L. Prevalence and impact of migrainous vertigo in mid-life women: a community-based study. Cephalalgia, 2011; 31(1): 77-83. doi: 10.1177/0333102410373152
    [19]
    Han D. Association of serum levels of calcitonin gene-related peptide and cytokines during migraine attacks. Ann Indian Acad Neurol, 2019; 22(3): 277-281. doi: 10.4103/aian.AIAN_371_18
    [20]
    Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology, 2013; 81(14): 1191-1196. doi: 10.1212/WNL.0b013e3182a6cb72
    [21]
    Olesen J, Diener H C, Husstedt I W, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med, 2004; 350(11): 1104-1110. doi: 10.1056/NEJMoa030505
    [22]
    Hoffmann J, Goadsby P J. New agents for acute treatment of migraine: cgrp receptor antagonists, inos inhibitors. Curr Treat Options Neurol, 2012; 14(1): 50-59. doi: 10.1007/s11940-011-0155-4
    [23]
    Villalon C M, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther, 2009; 124(3): 309-323. doi: 10.1016/j.pharmthera.2009.09.003
    [24]
    Ho T W, Edvinsson L, Goadsby P J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol, 2010; 6(10): 573-582. doi: 10.1038/nrneurol.2010.127
    [25]
    Akerman S, Romero-Reyes M, Holland P R. Current and novel insights into the neurophysiology of migraine and its implications for therapeutics. Pharmacol Ther, 2017; 172: 151-170. doi: 10.1016/j.pharmthera.2016.12.005
    [26]
    Russo A F. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol, 2015; 55(1): 533-552. doi: 10.1146/annurev-pharmtox-010814-124701
    [27]
    Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol, 2009; 8(7): 679-690. doi: 10.1016/S1474-4422(09)70090-0
    [28]
    Akerman S, Holland P R, Summ O, et al. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain, 2012; 135(Pt 12): 3664-3675.
    [29]
    Burstein R, Jakubowski M, Garcia-Nicas E, et al., Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol, 2010; 68(1): 81-91. doi: 10.1002/ana.21994
    [30]
    Sixt M L, Messlinger K, Fischer M J. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain, 2009; 132(Pt 11): 3134-3141. http://brain.oxfordjournals.org/cgi/reprint/awp168v1.pdf
    [31]
    Rossi C, Alberti A, Sarchielli P, et al. Balance disorders in headache patients: evaluation by computerized static stabilometry. Acta Neurol Scand, 2005; 111(6): 407-413. doi: 10.1111/j.1600-0404.2005.00422.x
    [32]
    Akdal G, Donmez B, Ozturk v, et al. Is balance normal in migraineurs without history of vertigo? Headache, 2009; 49(3): e419-e425. doi: 10.1111/j.1526-4610.2008.01256.x
    [33]
    Anagnostou E, Gerakoulis S, Voskou P, et al. Postural instability during attacks of migraine without aura. Eur J Neurol, 2019; 26(2): 319-321. doi: 10.1111/ene.13815
    [34]
    Balaban C D. Migraine, vertigo and migrainous vertigo: Links between vestibular and pain mechanisms. J Vestib Res, 2011; 21(6): 315-321. doi: 10.3233/VES-2011-0428
    [35]
    Balaban C D, Jacob R G, Furman J M. Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications. Expert Rev Neurother, 2011; 11(3): 379-394. doi: 10.1586/ern.11.19
    [36]
    Halberstadt A L, Balaban C D. Serotonergic and nonserotonergic neurons in the dorsal raphe nucleus send collateralized projections to both the vestibular nuclei and the central amygdaloid nucleus. Neuroscience, 2006; 140(3): 1067-1077. doi: 10.1016/j.neuroscience.2006.02.053
    [37]
    Goadsby P J, Lipton R B, Ferrari M D. Migraine--current understanding and treatment. N Engl J Med, 2002; 346(4): 257-270. doi: 10.1056/NEJMra010917
    [38]
    De Lacalle S, Saper C B. Calcitonin gene-related peptide-like immunoreactivity marks putative visceral sensory pathways in human brain. Neuroscience, 2000; 100(1): 115-130. doi: 10.1016/S0306-4522(00)00245-1
    [39]
    Richter F, Bauer R, Lehmenkuhler A, et al., Spreading depression in the brainstem of the adult rat: electrophysiological parameters and influences on regional brainstem blood flow. J Cereb Blood Flow Metab, 2008; 28(5): 984-994. doi: 10.1038/sj.jcbfm.9600594
    [40]
    May A, Goadsby P J. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab, 1999; 19(2): 115-127. doi: 10.1097/00004647-199902000-00001
    [41]
    Veronese N, Zanforlini B M, Manzato E, et al. Magnesium and healthy aging. Magnes Res, 2015; 28(3): 112-115. doi: 10.1684/mrh.2015.0387
    [42]
    Arnaud M J. Update on the assessment of magnesium status. Br J Nutr, 2008; 99(Suppl 3): S24-S36. http://www.onacademic.com/detail/journal_1000036815339910_e2a5.html
    [43]
    Volpe S L. Magnesium in disease prevention and overall health. Adv Nutr, 2013; 4(3): S378-S383. doi: 10.3945/an.112.003483
    [44]
    Lingam I, Robertson N J. Magnesium as a neuroprotective agent: a review of its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient. Dev Neurosci, 2018; 40(1): 1-12. doi: 10.1159/000484891
    [45]
    Köseoglu E, Talaslioglu A, Gönül A S, et al. The effects of magnesium prophylaxis in migraine without aura. Magnes Res, 2008; 21(2): 101-108. http://mineralmed.com.pt/documentos/pdf/3a24d700-574f-4b89-a0d9-dce7673c0681.pdf
    [46]
    Lodi R, IOTTI S, Cortelli P, et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull, 2001. 54(4): 437-441. doi: 10.1016/S0361-9230(01)00440-3
    [47]
    Coan E J, Collingridge G L. Magnesium ions block an N-methyl-D-aspartate receptor-mediated component of synaptic transmission in rat hippocampus. Neurosci Lett, 1985; 53(1): 21-26. doi: 10.1016/0304-3940(85)90091-6
    [48]
    Myrdal U, Leppert J, Edvinsson L, et al. Magnesium sulphate infusion decreases circulating calcitonin gene-related peptide (CGRP) in women with primary Raynaud's phenomenon. Clin Physiol, 1994; 14(5): 539-546. doi: 10.1111/j.1475-097X.1994.tb00412.x
    [49]
    Innerarity S. Hypomagnesemia in acute and chronic illness. Crit Care Nurs Q, 2000; 23(2): 1-19; quiz 87. doi: 10.1097/00002727-200008000-00002
    [50]
    Foster A C, Fagg G E. Neurobiology. Taking apart NMDA receptors. Nature, 1987; 329(6138): 395-396. doi: 10.1038/329395a0
    [51]
    Sato K, Momose-Sato Y. Optical detection of developmental origin of synaptic function in the embryonic chick vestibulocochlear nuclei. J Neurophysiol, 2003; 89(6): 3215-3224. doi: 10.1152/jn.01169.2002
    [52]
    Yuan H, Liu H, Hui H F, et al. Climatic variations and vertigo diseases in outpatients clinic of ENT. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2021; 35(2): 101-104. http://www.researchgate.net/publication/349096328_Climatic_variations_and_vertigo_diseases_in_outpatients_clinic_of_ENT
    [53]
    McCoy E S, Taylor-Blake B, Street S E, et al., Peptidergic CGRPalpha primary sensory neurons encode heat and itch and tonically suppress sensitivity to cold. Neuron, 2013; 78(1): 138-151. doi: 10.1016/j.neuron.2013.01.030
    [54]
    McCoy E S, Zylka M J. Enhanced behavioral responses to cold stimuli following CGRPalpha sensory neuron ablation are dependent on TRPM8. Mol Pain, 2014; 10: 69. http://mpx.sagepub.com/content/10/1744-8069-10-69.full.pdf
    [55]
    Nassini R, Materazzi S, Benemei S, et al. The TRPA1 channel in inflammatory and neuropathic pain and migraine. Rev Physiol Biochem Pharmacol, 2014; 167: 1-43. http://download.e-bookshelf.de/download/0003/9272/70/L-G-0003927270-0013264025.pdf
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (88) PDF downloads(7) Cited by()
    Proportional views
    Related

    Contact Us

    Editorial Office: Frigid Zone Medicine, Editorial Office of Frigid Zone Medicine, Heilongjiang Health Development Research Center, Zhongshan Road 112, Xiangfang District, Harbin, 150036, China

    Tel: 0451-87253028

    E-mail: editorialoffice@frigidzonemedicine.com

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    Links

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return